MX391116B - Composición de liberación sostenida que comprende tolcapona micronizada. - Google Patents
Composición de liberación sostenida que comprende tolcapona micronizada.Info
- Publication number
- MX391116B MX391116B MX2019001190A MX2019001190A MX391116B MX 391116 B MX391116 B MX 391116B MX 2019001190 A MX2019001190 A MX 2019001190A MX 2019001190 A MX2019001190 A MX 2019001190A MX 391116 B MX391116 B MX 391116B
- Authority
- MX
- Mexico
- Prior art keywords
- tablet
- sustained
- release composition
- transthyretin
- prevention
- Prior art date
Links
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004603 tolcapone Drugs 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- 239000003826 tablet Substances 0.000 abstract 4
- 108010071690 Prealbumin Proteins 0.000 abstract 3
- 102000009190 Transthyretin Human genes 0.000 abstract 3
- 206010002022 amyloidosis Diseases 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000007939 sustained release tablet Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382372.7A EP3275433A1 (en) | 2016-07-29 | 2016-07-29 | Sustained release composition comprising micronized tolcapone |
| PCT/EP2017/069168 WO2018019997A1 (en) | 2016-07-29 | 2017-07-28 | Sustained release composition comprising micronized tolcapone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019001190A MX2019001190A (es) | 2019-09-06 |
| MX391116B true MX391116B (es) | 2025-03-21 |
Family
ID=56571284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001190A MX391116B (es) | 2016-07-29 | 2017-07-28 | Composición de liberación sostenida que comprende tolcapona micronizada. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11883538B2 (OSRAM) |
| EP (2) | EP3275433A1 (OSRAM) |
| JP (1) | JP7047236B2 (OSRAM) |
| KR (1) | KR102484678B1 (OSRAM) |
| CN (1) | CN109789100A (OSRAM) |
| AU (1) | AU2017303333B2 (OSRAM) |
| DK (1) | DK3490535T3 (OSRAM) |
| ES (1) | ES2891355T3 (OSRAM) |
| MX (1) | MX391116B (OSRAM) |
| PT (1) | PT3490535T (OSRAM) |
| RU (1) | RU2750670C2 (OSRAM) |
| WO (1) | WO2018019997A1 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025536853A (ja) * | 2022-10-10 | 2025-11-07 | コリノ セラピューティクス，インク． | 放出調節トルカポン処方剤 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| NZ332861A (en) | 1996-05-20 | 2000-08-25 | G | Potassium, sodium and tris oxaprozin salt pharmaceutical formulations |
| AU3705799A (en) * | 1998-04-09 | 1999-11-01 | F. Hoffmann-La Roche Ag | Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants |
| US6599530B2 (en) * | 1998-09-14 | 2003-07-29 | Orion Corporation | Oral compacted composition comprising catechol derivatives |
| GB2348371B (en) * | 2000-03-14 | 2001-04-04 | Soares Da Silva Patricio | Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease |
| JP2006521287A (ja) * | 2002-12-20 | 2006-09-21 | エスティ．ジェイムス アソシエイト エルエルシー／フェイバー リサーチ シリーズ | 医薬製剤用の高圧圧縮 |
| JP5336181B2 (ja) * | 2005-06-08 | 2013-11-06 | オリオン コーポレーション | 経口投薬形態 |
| CA2673485A1 (en) * | 2007-01-15 | 2008-07-24 | Kissei Pharmaceutical Co., Ltd. | Gastric retention-type sustained-release levodopa preparation |
| SMT201800145T1 (it) * | 2010-11-15 | 2018-05-02 | Neuroderm Ltd | Somministrazione continua di l-dopa, di inibitori della dopa decarbossilasi, di inibitori della catecol-o-metil trasferasi e composizioni per essa |
| WO2012125598A1 (en) | 2011-03-14 | 2012-09-20 | Boehringer Ingelheim International Gmbh | Benzodioxane inhibitors of leukotriene production |
| SG11201401215VA (en) * | 2011-10-24 | 2014-08-28 | Som Innovation Biotech S L | New therapy for transthyretin-associated amyloidosis |
| US20130195973A1 (en) * | 2012-01-30 | 2013-08-01 | Ranbaxy Laboratories Limited | Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof |
| AU2014229127B2 (en) * | 2013-03-13 | 2018-04-05 | Neuroderm Ltd | Method for treatment of parkinson's disease |
| WO2015069773A1 (en) * | 2013-11-05 | 2015-05-14 | Synagile Corporation | Devices and methods for continuous drug delivery via the mouth |
| ES2844500T3 (es) * | 2014-09-04 | 2021-07-22 | Lobsor Pharmaceuticals Ab | Composiciones farmacéuticas que comprenden levodopa, un inhibidor de dopamina decarboxilasa y un inhibidor de COMT, y método de administración de las mismas |
-
2016
- 2016-07-29 EP EP16382372.7A patent/EP3275433A1/en not_active Withdrawn
-
2017
- 2017-07-28 JP JP2019526375A patent/JP7047236B2/ja active Active
- 2017-07-28 WO PCT/EP2017/069168 patent/WO2018019997A1/en not_active Ceased
- 2017-07-28 KR KR1020197004664A patent/KR102484678B1/ko active Active
- 2017-07-28 CN CN201780060604.7A patent/CN109789100A/zh active Pending
- 2017-07-28 RU RU2019103647A patent/RU2750670C2/ru active
- 2017-07-28 PT PT177433588T patent/PT3490535T/pt unknown
- 2017-07-28 AU AU2017303333A patent/AU2017303333B2/en active Active
- 2017-07-28 US US16/321,336 patent/US11883538B2/en active Active
- 2017-07-28 ES ES17743358T patent/ES2891355T3/es active Active
- 2017-07-28 EP EP17743358.8A patent/EP3490535B1/en active Active
- 2017-07-28 MX MX2019001190A patent/MX391116B/es unknown
- 2017-07-28 DK DK17743358.8T patent/DK3490535T3/da active
-
2024
- 2024-01-29 US US18/425,739 patent/US12220487B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3275433A1 (en) | 2018-01-31 |
| RU2019103647A (ru) | 2020-08-28 |
| AU2017303333B2 (en) | 2023-03-30 |
| CA3032211A1 (en) | 2018-02-01 |
| CN109789100A (zh) | 2019-05-21 |
| US12220487B2 (en) | 2025-02-11 |
| DK3490535T3 (da) | 2021-10-04 |
| ES2891355T3 (es) | 2022-01-27 |
| PT3490535T (pt) | 2021-09-30 |
| WO2018019997A1 (en) | 2018-02-01 |
| EP3490535B1 (en) | 2021-07-14 |
| KR20190034563A (ko) | 2019-04-02 |
| MX2019001190A (es) | 2019-09-06 |
| US20240216282A1 (en) | 2024-07-04 |
| JP7047236B2 (ja) | 2022-04-05 |
| BR112019001826A2 (pt) | 2019-05-07 |
| RU2019103647A3 (OSRAM) | 2020-10-12 |
| JP2019523305A (ja) | 2019-08-22 |
| EP3490535A1 (en) | 2019-06-05 |
| KR102484678B1 (ko) | 2023-01-03 |
| US20190167596A1 (en) | 2019-06-06 |
| US11883538B2 (en) | 2024-01-30 |
| RU2750670C2 (ru) | 2021-06-30 |
| AU2017303333A1 (en) | 2019-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011104A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| MX2018003594A (es) | Anticuerpo anti-garp. | |
| MX2022012931A (es) | Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5. | |
| EP3640246A4 (en) | N2, N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, PROCESS OF PREPARATION, AND PHARMACEUTICAL COMPOSITION CONTAINING IT AS ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER | |
| BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
| BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
| MX386413B (es) | Combinaciones terapéuticas que comprenden un inhibidor de raf y un inhibidor de erk. | |
| CL2018000222A1 (es) | Nueva combinación para el uso en el tratamiento del cáncer | |
| MX373330B (es) | Composiciones y métodos que comprenden bupropion o compuestos relacionados y dextrometorfano. | |
| CL2016000378A1 (es) | Composiciones y métodos terapéuticos para la regresión acelerada de placa | |
| MX2015016627A (es) | Vacuna para la malaria. | |
| BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
| MX2016013236A (es) | Formulacion inmunosupresora. | |
| BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| CR20160047A (es) | Inhibidores de rorc2 y sus métodos de uso | |
| CL2017000682A1 (es) | Compuestos novedosos de imidazopiridazina y su uso. | |
| MX2019012938A (es) | Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores. | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| BR112017015159A2 (pt) | preparação e uso de produtos plaquetários | |
| UY37449A (es) | Anticuerpos anti-chikv y usos de éstos | |
| MX387658B (es) | Métodos para tratar y/o prevenir queratosis actínica. | |
| MX2017003469A (es) | Inhibidores macrociclicos de cinasa rip2. | |
| CO2018002428A2 (es) | Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol | |
| CL2019003288A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer. | |
| ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación |